• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

PRODUCT FILTERS

REGION

1
1
1
1
1

CATEGORIES

  • 4

PRICE

4
4
4
4

PUBLISHED

0
0
0
4

PRODUCT TYPE

4

Search "Chelyabinsk Oblast Dec 11" returned 4 results.

PRODUCT TITLE
Chelyabinsk Oblast Dec 11 Chelyabinsk Oblast Dec 11 - Product Thumbnail Image

Chelyabinsk Oblast Dec 11

Abstract Sound budgetary performance. Very low debt burden. Positive liquidity position. Economic and tax-base concentration. Limited budgetary flexibility owing to a developing and unbalanced institutional...

December 2011
Summary: Chelyabinsk Oblast Dec 11 Summary: Chelyabinsk Oblast Dec 11 - Product Thumbnail Image

Summary: Chelyabinsk Oblast Dec 11

Abstract The ratings on Chelyabinsk Oblast, an industrial region in Russia's Urals Federal District, reflect our view of its low budgetary flexibility and predictability under Russia's developing and...

December 2011
Local And Regional Government Ratings In Europe, The Middle East, And Africa Dec 11 Local And Regional Government Ratings In Europe, The Middle East, And Africa Dec 11 - Product Thumbnail Image

Local And Regional Government Ratings In Europe, The Middle East, And Africa Dec 11

Abstract Standard & Poor's Ratings Services rates 140 local and regional governments (LRGs) in Europe, the Middle East, and Africa, as shown in the table below. Apart from pure LRGs, the issuers listed...

December 2011
Institutional Framework Assessments For International Local And Regional Governments Dec 11 Institutional Framework Assessments For International Local And Regional Governments Dec 11 - Product Thumbnail Image

Institutional Framework Assessments For International Local And Regional Governments Dec 11

Abstract Standard & Poor's Ratings Services has completed its periodical review of our institutional framework assessments for the local and regional governments (LRGs) we rate worldwide. Since we...

December 2011
Loading Indicator

Our Clients

Amneal Pharmaceuticals LLC. Amgen Inc. LEO Laboratories Ltd. Pfizer, Inc. Roche Diagnostics Ltd. Merck & Co., Inc. Sanofi S.A.